Aussies test BRCA prophylaxis theory

Melbourne researchers are recruiting 30 women with a BRCA gene mutation to test their theory that RANK ligand inhibition with drugs such as denosumab  could be protective against breast cancer.

The team from The Royal Melbourne Hospital and Walter and Eliza Hall Institute hope an inhibitor will deactivate progenitor cells, which they have previously identified as possible cancer culprits among BRCA carriers.

“It is a pilot three-month proof-of-principle clinical trial,” says the institute’s Professor Geoff Lindeman. “We